Synergies between Vaxeal and its partners will improve patient access to new advanced immunotherapies.


A central aim of modern cancer therapies is the induction of effective an anti-tumour immunity in cancer patients leading to the elimination of tumors and long-lasting protection against relapses. In this regard, modern therapeutic vaccination has been shown to elicit tumor antigen specific T-cell immunity.

Nevertheless, cancer vaccines are showing modest clinical effects such as objective tumor responses in a small proportion of immunized patients and increase in overall survival for a few vaccines.

Many studies have identified the two main sets of hurdles in cancer vaccine development. The first arises from the sub-optimal composition and design of the tumor antigen-based vaccines leading to their weak immunogenicity and difficulty in generating robust memory responses and in achieving the right balance of CD4+ and CD8+ T-cell responses. The second set of hurdles is the tumor-induced immunosuppressive mechanisms such as:

The induction of regulatory T-cells (Treg) in the tumour micro-environment,

The over-expression of multiple immune regulatory checkpoints operating intrinsically in antigen activated T-cells and extrinsically within the tumour micro-environment, and

The tumor-mediated angiogenesis.


Vaxeal has developed exceptional and innovative technology platforms for:

  • A rapid identification of relevant T-cell epitopes to be incorporated into the vaccine candidates;
  • The design, formulation and validation of vaccine candidates;
  • The evaluation of synergistic combination of the formulated vaccines with immunomodulatory agents;
  • Pre-clinical proof of concept studies; and
  • The immunomonitoring of clinical trials.


Vaxeal’s core expertise in vaccine design, antigen formulation, delivery systems and immuno-modulatory drugs has allowed the management team to identify the optimal and innovative combined strategy for the design of cancer fixed combined immunotherapies, overcoming the limitations of current cancer vaccine-based approaches. This include:

  1. To design of Long Synthetic Peptides (LSP) containing several immunogenic peptides sequences, called T-cell epitopes, derived from relevant target protein.
  1. To optimize vaccine formulation with potent immuno-adjuvant, delivery systems to improve the polarization and longevity of the vaccine-induced T-cell responses.
  1. To use a synergistic fixed combination with immunomodulatory drugs to limit tumor-mediated immuno-suppressive mechanisms.